Rho and Rab families possess a third class of regulatory proteins, guanine nucleotide dissociation inhibitors, which are beyond the scope of this Review.
The best validated connection between small GTPases and cancer comprises the three Ras proteins 5 . Mutational activation of Ras is found in ~33% of human cancers (collated from the Catalogue of Somatic Mutations (COSMIC) database (see the COSMIC database; Further information) 6 . Consequently, there have been intensive efforts to identify pharmacological approaches to block Ras function for cancer treatment. To date, no successful 'anti-Ras' strategies have reached the clinic. The low micromolar binding affinity of protein kinases for ATP, for which potent nanomolar affinity ATP-competitive inhibitors have been developed (imatinib, for example), has been a very successful avenue for anticancer drug development 7 . By contrast, the low picomolar binding affinity of small GTPases for GTP and milimolar cellular concentrations of GTP renders a similar strategy for Ras implausible 8 . Thus, past and current efforts have focused on indirect approaches for the disruption of Ras function: the inhibition of components that regulate Ras membrane association 9 and the inhibition of downstream effector signalling 10 
(FIG. 2).
Beyond Ras, the aberrant function of an increasing list of Ras superfamily proteins has been implicated in human cancer growth and development. However, whereas mutational activation of Ras is commonly seen in human cancers, direct mutation of other Ras superfamily GTPases is not frequently observed. Instead, the deregulated gene expression and/or deregulated protein function of GEFs and GAPs, in particular for specific Ras and Rho family proteins and also the Arf family 11, 12 , has been found to have important roles in cancer (Supplementary information S1,S2 (tables) lists the mechanisms and roles of GEF and GAP deregulation in human cancers). Genomewide sequence analyses of breast, colon, pancreatic and brain cancers have now been completed [13] [14] [15] [16] , and a search of the COSMIC database reveals isolated mutations in numerous GEFs and GAPs from sequence analyses of 173 regulators of Ras superfamily GTPases. However, whether these mutated genes are passengers or drivers of oncogenesis, and whether they encode proteins with altered function, is not known for most.
In this Review, we summarize the representative studies in which aberrant GEF or GAP function is observed in cancer cells and in which sufficient validation has been carried out to show the causal roles of individual GEFs or GAPs in the aberrant growth properties of human cancer cells or in mouse models of cancer. We primarily focus on Ras and Rho family GTPases and summarize the current evidence validating a causal role for their regulators in causing aberrant small GTPase function in human cancer or cancer-associated processes. We also discuss the issues surrounding the pharmacological manipulation of GEF or GAP function. Our conventional targets and approaches for anticancer drug discovery have been hampered by tradition and past success. Although it is still early days in terms of target validation, and our current success in therapeutic targeting of these regulators is more proofof-concept than clinical reality, we believe that GEFs and GAPs hold exciting prospects for cancer therapy.
GEFs in cancer
The potential involvement of GEFs in cancer was first suggested by the isolation of RhoGEFs [17] [18] [19] [20] , and later RasGEFs [21] [22] [23] , as transforming proteins in expression library functional screens using genomic DNA or mRNA derived from human cancer cells. However, the identified transforming RhoGEFs were activated by genomic deletion of coding sequences during the process of experimental manipulation rather than owing to genetic events that occurred in the cancer cells 24 . Nevertheless, these observations supported their potential role as oncogenes in cancer development. As GEF activation is the most common mechanism for signal-mediated GTPase activation, the theme that has emerged is that aberrant signalling from growth factor receptors, in particular transmembrane receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs), leads to aberrant GEF regulation, which contributes to small GTPase activation in cancer. Another common mechanism of aberrant GEF activation is upregulated gene expression, and to a lesser degree missense mutations and the consequent expression of catalytically altered GEFs (Supplementary information S1 (table)). Although it is possible that there is upregulation of Ras or Rho GTPase activity by multiple GEFs simultaneously or that there is inactivity of multiple GAPs (because there are many family members that could regulate the same GTPases) we present examples in which the roles of individual GEFs or GAPs are clear.
RasGEFs associated with cancer. RasGEFs activate
Ras and may also function as GEFs for the related Rap and Rras, but not Ral, subfamily members of the Ras superfamily. The most common mechanism by which RasGEFs are involved in cancer involves their activation by growth factor-activated cell surface RTKs or GPCRs. This is best represented by the classical Ras signalling pathway, in which activation of the epidermal growth factor receptor (EGFR) causes activation of wild-type Ras through growth factor receptor-bound protein 2 (GRB2)-mediated activation of the two RasGEFs son of sevenless homologue 1 (SOS1) and SOS2. EGFR overexpression, mutational activation or hyperactivation by autocrine mechanisms are commonly seen in many cancers, leading to persistent Ras activation 25 . RTK and GPCR activation can also activate Ras through the downstream activation of phospholipase Cγ1 (PlCγ1) and PlCβ1, respectively. PlC activation and subsequent diacylglycerol production directly activates the Ras guanyl releasing protein (RasGRP) subfamily of RasGEFs 26 . Mutationally activated Ras may also still require RasGEF activity, perhaps to concurrently activate wild-type Ras isoforms 27 . Germline gain-of-function mutation of the RasGEF SoS1 has been observed in 13% of patients with Noonan syndrome, a developmental disorder that is also associated with an increased risk of cancer 28, 29 . This implies that SOS1 could be an oncoprotein. However, an extensive sequence analysis of samples from 810 primary malignancies found only three SoS1 mutations and concluded that SOS1 mutational activation is not common in human cancers 30 . Therefore, similar to other mutations found in developmental syndromes that activate KRAS, RAF1 (also known as CRAF), MEK1 (also known as MAPKK1) and MEK2 (also known as MAPKK2), the SOS1 mutations are weakly activating and might not be
At a glance
• There is increasing evidence that the aberrant activity of numerous members of the Ras superfamily of small GTPases contributes to cancer growth, invasion and metastasis.
• Unlike the frequent direct mutational activation of the three Ras proteins (which occurs in ~33% of human cancers), other Ras superfamily GTPases are deregulated by indirect mechanisms, commonly involving the altered expression or activity of their regulatory proteins.
• Guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) that control the GDP-GTP cycling of specific members of the Ras superfamily have been shown to contribute to cancer by either promoting or suppressing tumour progression and growth.
• GEFs and GAPs are deregulated in cancer by somatic mutation, changes in gene expression and through post-translational mechanisms owing to aberrant signalling caused by alterations in upstream oncogene or tumour suppressor function.
• Although GEFs and GAPs are not considered classically druggable targets, there is growing evidence that supports the feasibility of targeting them. For example, nature has provided examples (such as brefeldin A) that provide proof-of-principle of GEF and GAP druggability.
• The multi-domain structures of GEFs and GAPs contribute to their regulation by diverse signalling mechanisms and might also identify therapeutic approaches for pharmacological regulation of GEF and GAP activity in cancer. 
CDC25 homology domain
RasGEF catalytic domain, named after the first protein it was identified in: CDC25 in Saccharomyces cerevisiae.
Matrigel
The trade name for a gelatinous protein mixture that is secreted by mouse tumour cells. It resembles the complex extracellular environment found in many tissues and is commonly used as a three-dimensional matrix substrate for cell culture-based in vitro migration and invasion assays.
CAAX motif
C-terminal tetrapeptide sequence comprised of a cysteine, followed by two aliphatic amino acids and a terminal X residue that dictates specificity for farnesyltransferase or geranylgeranyltransferase-I catalysed addition of a C15 farnesyl or C20 geranylgeranyl isoprenoid lipid.
potent enough to cause cancer 31 . Mutations in other RasGEFs are also rare in cancer (see Supplementary information S1 (table) and the COSMIC database (see Further information)).
Finally, another association between RasGEFs and cancer involves their roles as downstream effectors of Ras (FIG. 3) . PlCε1, a downstream effector of Ras [32] [33] [34] , contributes to mutant HRAS-mediated skin tumour formation; whether its RasGEF activity is relevant for this role is not known. However, caution in interpreting these experiments is warranted, as follow-up studies found that PlCε1 loss reduced a stromal tissue inflammatory response and that isolated PlCε1-deficient keratinocytes had no reduction in proliferative capacity 35 . Therefore, whether PlCε1 loss caused reduced tumorigenesis in its role as a crucial downstream Ras effector in cancer cells, or whether it serves a tumour cell autonomous function, is unclear. Additionally, although there is evidence that PlCε1 can activate Ras, most evidence supports its role as a Rap activator 36 . Other CDC25 homology domain-containing RasGEFs that are not activators of Ras but are instead activators of the RAlA and RAlB small GTPases (also members of the Ras GTPase superfamily) include Ral guanine nucleotide dissociation stimulator (RAlGDS), Ral guanine nucleotide dissociation stimulator-like 1 (RGl1), RGl2 and RGl3 (REF. 37 ) (see Supplementary information S3 (figure)). Mice deficient in RAlGDS show impaired tumour formation in mutationally activated HRAS-driven skin tumour formation 38 . RGl2 overexpression was described in pancreatic tumours and cell lines, and suppression of RGl2 expression impaired tumour cell anchorage-independent growth and Matrigel invasion 39 . Moreover, Ral GTPases are activated in
Box 1 | The Ras superfamily of small GTPases
The human Ras superfamily is comprised of 154 members, which are divided into five major branches on the basis of sequence and functional similarities 1,2 (see part a of the figure). The Ras family are involved in signal transduction, the regulation of gene expression, cell proliferation, survival and differentiation. Rho GTPases are involved in signal transduction, the regulation of actin organization, cell shape and polarity, movement, and cell-cell and cell-matrix interactions. Rab GTPases are involved in vesicular trafficking, regulating endocytosis and secretory pathways. Arf GTPases are also involved in vesicular trafficking, regulating endocytosis and secretory pathways, as well as microtubule dynamics. The Ran GTPase is involved in nuclear-cytoplasmic transport and mitotic spindle organization. In addition to the three Ras isoforms, other members of the Ras family with important roles in cancer include the Ras homologue enriched in brain (RHEB) and Ral GTPases. The ~20 kDa core G domain (corresponding to Ras residues 4-166) is conserved among all Ras superfamily proteins and is involved in GTP binding and hydrolysis 149 (see part b of the figure). This domain is comprised of five conserved guanine nucleotide consensus sequence elements that are involved in binding phosphate and Mg 2+ (PM) or guanine (G). The switch I (SI; Ras residues 30-38) and SII (Ras residues 59-76) regions change in conformation during GDP-GTP cycling and contribute to preferential effector binding to the GTP-bound state and the core effector domain (E; Ras residues 32-40). Ras and Rho family GTPases have additional carboxy-terminal hypervariable (HV) sequences that commonly terminate with a CAAX motif that signals for a farnesyl or geranylgeranyl isoprenoid addition to the cysteine residue, proteolytic removal of the AAX residues and carboxyl methylation of the prenylated cysteine. Some are additionally modified by a palmitate fatty acid to cysteine residues in the HV sequence that contributes to membrane association. Rab GTPases also contain a C terminal HV region that terminates with cysteine-containing motifs that are modified by the addition of geranylgeranyl lipids, with some undergoing carboxyl methylation. Arf family GTPases are characterized by an amino-terminal extension that is involved in membrane interaction, with some co-translationally modified by the addition of a myristate fatty acid. Ran is not lipid modified but contains a C terminal extension that is essential for function. Rho proteins are characterized by an up to 13 amino acid 'Rho insert' sequence that is positioned between Ras residues 122 and 123 and is involved in effector regulation. Nature Reviews | Cancer 
Organotypic
Resembling an organ in vivo, either morphologically or functionally, or both.
human tumours and promote the growth of bladder, pancreatic, prostate and other cancers [40] [41] [42] [43] . Ral GTPases function as GDP-GTP-regulated binary switches that are regulated by distinct GEFs and GAPs and activate distinct downstream effectors that modulate endocytosis, exocytosis and actin organization. Thus, targeting GTPase activation by GEFs or GTPase activation of GEF effectors are two potential applications of GEF inhibitors (see Supplementary information S4 (figure)).
RhoGEFs associated with cancer. It is now clear that Rho GTPases have a major role in many different aspects of tumorigenesis 44, 45 . Most Rho GTPases promote tumorigenesis, and thus hyperactivation of their GEFs would likewise be oncogenic. However, there are examples, such as RHOB, that exert tumour suppressor effects, and so activation of their GEFs would also be considered tumour suppressive. unlike the Ras family, which is mutated in a large proportion of human cancers, mutations in Rho GTPases are rare. Instead, Rho GTPase hyperactivation can occur through overexpression, loss of GAP-mediated inactivation and upstream activation (FIG. 4) or through overexpression of the RhoGEFs. Below, we highlight some examples (see also Supplementary information S1 (table)).
Vav RhoGEFs have been implicated in the growth of several cancers. First, the normally haematopoietic cellspecific VaV1 was overexpressed in pancreatic carcinoma cells as a consequence of promoter demethylation, leading to Rac activation and signalling 46 . SRC-dependent phosphorylation of VAV1, which was activated by EGFR, has been shown to activate a Rac-p21-activated kinase (PAK)-nuclear factor-κB (NF-κB) signalling pathway and cyclin D1 upregulation. RNA interference (RNAi)-mediated depletion of VAV1 abrogated anchorage-independent growth in vitro and tumour growth in mouse xenografts. Moreover, VAV1 expression in pancreatic carcinomas was associated with decreased survival. The related RhoGEF VAV2 is hyperactivated in head and neck squamous cell carcinoma (HNSCC) through an autocrine loop that is dependent on EGFR. Knock down of VAV2 inhibited RAC1 activation and EGFRstimulated invasion through Matrigel 47 . Another member, VaV3, was overexpressed at the mRNA and protein level in human glioblastomas compared with unmatched normal brain samples; knock down in cell lines decreased migration in vitro and in an ex vivo organotypic brain slice invasion assay 48. Finally, Vav2 -/-;Vav3 -/--double knockout mice had reduced xenograft tumour growth when transplanted with human lung or melanoma cells, partly owing to deficient angiogenesis, which largely resulted from a defect in tumour-induced endothelial cell migration 49 . This suggests a role for RhoGEF signalling in the host microenvironment, highlighting the many ways in which RhoGEFs might affect tumorigenesis.
A Rac-specific GEF, phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 (PREx1), has been implicated in prostate cancer cell invasion 50 . The three Rac isoforms (RAC1-3) are known to be important in many cancers through various ways, including
Box 2 | The GDP-GTP cycle
Ras superfamily proteins possess intrinsic guanine nucleotide exchange and GTP hydrolysis activities. However, these activities are too weak to allow efficient and rapid cycling between their active GTP-bound and inactive GDP-bound states. Guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) catalyse and regulate these intrinsic activities. Members of the different branches of the Ras superfamily are regulated by GEFs and GAPs with structurally distinct catalytic domains 3, 4, [150] [151] [152] [153] . In the figure the Rho family is used as an example to illustrate the complexity of this process, in which multiple GEFs and GAPs may regulate one specific GTPase. For the 20 human Rho GTPases there are 83 GEFs and 67 GAPs, and a subset of Rho GTPases are not likely to be regulated by GEFs and GAPs (such as RnD3; also known as RHoE). Rho GTPases are activated by distinct RhoGEF families. Dbl family RhoGEFs (of which there are 68) possess a tandem Dbl homology (DH) catalytic and pleckstrin homology (PH) regulatory domain topology. Dedicator of cytokinesis (Dock) family RhoGEFs (of which there are 11) are characterized by two regions of high sequence conservation that are designated Dock-homology region regulatory (DHR1) and catalytic (DHR2) domains. Two other RhoGEFs have been described: switch-associated protein 70 (SWAP70) and SLAT (also known as DEF6) contain a PH but no DH domain; SMG GTP-GDP dissociation stimulator (SMGGDS: also known as RAP1GDS1) is an unusual GEF in that it functions as a GEF for some Rho GTPases, as well as for non-Rho GTPases. At least 24 Dbl RhoGEFs have been reported to activate RHoA 152 . Rho (and Rab) GTPases are also controlled by a third class of regulatory proteins, Rho dissociation inhibitors (RhoGDIs; of which there are three) the main function of which involves the regulation of Rho GTPase membrane association by masking the isoprenoid group. E, effector; G, geranylgeranyl isoprenoid. 
Dbl homology (DH) domain
The RhoGEF catalytic domain, named after the first protein it was identified in, the Dbl protein encoded by a transforming gene identified from an NIH 3T3 focus formation assay using genomic DNA from a human diffuse B cell lymphoma.
Pleckstrin homology (PH) domain
A sequence of approximately 100 amino acids that is present in many signalling molecules and that commonly binds to phospholipids and proteins.
stimulating migration and invasion by inducing lamellipodia, as well as growth 51 . PRex1 gene and protein expression was highest in metastatic prostate cancer cell lines, and protein expression was highest in metastatic prostate tumour tissue. Suppression of endogenous PRex1 expression in the PC-3 metastatic prostate cancer cell line inhibited Rac activity and reduced ligand-stimulated cell migration and invasion in vitro and ectopic PRex1 overexpression in PC-3 cell xenografts did not enhance tumorigenic growth but did promote metastasis to lymph nodes. In addition, PRex1 overexpression was associated with the activation of ERK-MAPK signalling in melanomas 52 . Finally, a recent study has identified the related PREx2 as a binding partner for the PTEN tumour suppressor 53 . PTEN is a lipid phosphatase that converts phosphatidylinositol-3,4,5-trisphosphate to phosphatidylinositol-4,5-bisphosphate and thus antagonizes PI3K activity. PRex2 mRNA was overexpressed in PTeN wildtype breast cancers, and RNAi-mediated depletion of PREx2 reduced the levels of activated AKT and impaired the growth of PTEN wild-type tumours. Taken together, these studies with Rac-selective GEFs underscore their importance in migration, invasion and metastasis.
The mRNA or protein of epithelial cell transforming sequence 2 oncogene (ECT2) -an activator primarily of RHOA, but also of Rac and cell division cycle 42 (CDC42) 54, 55 -has been found to be overexpressed in various human tumour cell lines and tissues, including in lung and oesophageal squamous cell carcinomas 48, [56] [57] [58] [59] , and overexpression correlated with poor prognosis 57, 58 . eCT2 mRNA and protein overexpression was found in samples from patients with glioblastoma compared with non-matched normal brain tissue, and RNAi-mediated suppression of ECT2 expression in glioblastoma cells reduced migration and growth rates in vitro and invasion in an ex vivo organotypic rat brain slice model 48 . Finally, a recent study found eCT2 mRNA and protein overexpression in samples of non-small-cell lung carcinomas (NSClCs) 60 . ECT2 expression was mislocalized to the cytoplasm and was associated with Rac activation but surprisingly not with RHOA activation. RNAi-mediated knock down of ECT2 in NSClC cell lines blocked the anchorage-independent growth and Matrigel invasion in vitro, and xenograft tumour growth in vivo.
Three different RhoGEFs are structurally mutated in human cancers by chromosome rearrangement and the formation of chimeric fusion proteins. One involves the RHOA-specific GEF ARHGEF12 (also known as lARG), which was initially identified in tumour cells from a patient with acute myelogenous leukaemia 61 . The rearrangement encodes a mixed-lineage leukaemia (Mll)-ARHGEF12 fusion protein that retains the catalytic domains of ARHGEF12 -the Dbl homology (DH) domain and pleckstrin homology (PH) domain. Whether the fusion protein is a constitutively activated variant of ARHGEF12 has not been determined. ARHGEF12 and the related PDZ domain-containing RhoGEFs ARHGEF1 (also known as p115-RhoGEF) and ARHGEF11 (also known as PDZ-RhoGEF)) might also be activated by GPCRs that are coupled to Gα 12 or Gα 13 , or by Gα 12 and Gα 13 overexpression 62, 63 (FIG. 4) . The second example is the breakpoint cluster region (BCR)-ABl1 fusion protein that is encoded by the translocation that is associated with the Philadelphia chromosome, which is found in 90% of chronic myelogenous leukaemias. BCR possesses a RhoGEF and a RhoGAP domain, and ABl1 is a protein tyrosine kinase. In the resulting BCR-ABl1 chimera, the RhoGEF but not the RhoGAP domain is retained and fused to truncated ABl1, resulting in constitutive activation of the kinase activity that is crucial for BCRABl1-mediated oncogenesis. BCR-ABl1 transforming activity, as measured by anchorage-independent growth, is also partially dependent on the RhoGEF activity, which results in the activation of RHOA 64 . Finally, a third RhoGEF, triple functional domain protein (TRIO), is activated in adult T cell leukaemias by alternative splicing, which results in a truncated protein with the second catalytic DH domain attached to a unique 15-residue Figure 1 | GeFs and GaPs are multi-domain proteins. This figure focuses on those guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) for which some degree of validation has been accomplished, and parallels those listed in Supplementary information S1, S2 (tables). A key point of this figure is to emphasize the complex domain topology of GEFs and GAPs. Beyond their shared catalytic domains, there is considerable diversity in the structure of GEFs and GAPs for a specific GTPase. This diversity is especially striking for RhoGEFs 152 and RhoGAPs 3 . These flanking domains or motifs are often involved in promoting their activation by upstream signals (such as Ras-binding or association domains). The domains include those that promote protein-protein interactions (such as Src homology 2 (SH2) and SH3 domains) or protein-lipid interactions, second messenger binding and protein kinase phosphorylation sites. These interactions may facilitate association with specific subcellular membranes or compartments, regulating spatially restricted GTPase activation. These interactions may also regulate autoregulatory sequences or allosteric regulation of GAP or GEF catalytic activity. Others may influence the effectors used by the GTPases. Some contain additional catalytic domains. For example, some RasGEFs also contain Dbl homology (DH)-pleckstrin homology (PH) domains and can activate Rho GTPases. Therefore, it is likely that GEFs and GAPs will have GEF-independent or GAP-independent functions and might be regulated by GTPase-independent mechanisms. Thus, caution should be exercised when using RNA interference to suppress their expression and ascribing cellular activities simply to GTPase activity. For descriptions of domain abbreviations and functions, the reader is referred to the SMART website (see Further information). ABR, adenomatous polyposis coli (APC) binding region; ANK, ankyrin repeat domain; ARFGEF2, ADP-ribosylation factor guanine nucleotide-exchange factor 2 (also known as BIG2); BAR, Bin1/amphiphysin/Rvs167 domain; BCR, breakpoint cluster region; BRCT, BRCA1 C-terminus domain; CC, coiled-coil domain; CDC25, cell division cycle 25 homology domain; CH, calponin homology domain; CR, cysteine-rich domain; DBS, DBL's big sister; DHR, DOCK homology region; DLC1, deleted in liver cancer 1 (also known as ARHGAP7); DOCK, dedicator of cytokinesis; ECT2, epithelial cell transforming sequence 2 oncogene; FBX8, F-box protein 8; Ig, immunoglobulin domain; IQSEC1, IQ motif and Sec7 domain 1 (also known as GEP100); IQGAP1, IQ motif containing GAP1; NET1, neuroepithelial cell transforming 1 (also known as ARHGEF8); NF1, neurofibromin; OBSCN, obscurin; PI(3,4,5) P 3 BD, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase binding domain; PLCε1, phospholipase Cε1; PLXNB1, plexin B1; PREX, phosphatidylinositol-3,4,5-trisphosphatedependent Rac exchange factor; Pro, proline-rich domain; PSD, pleckstrin and Sec7 domain containing (also known as EFA6); PSI, plexin/semaphorin/integrin domain; RA, Ras association domain; RALBP1, RALA binding protein 1; RALGDS, Ral guanine nucleotide dissociation stimulator; RASAL, Ras protein activator like; RASGRF2, Ras protein-specific guanine nucleotide-releasing factor 2; RASGRP, RAS guanyl releasing protein; RBD, Ras binding domain; REM, Ras exchanger motif; RGL, Ral guanine nucleotide dissociation stimulator-like; RGR, Ral-GDS-related protein; SIPA1, signal-induced proliferation-associated 1; SOS1, son of sevenless homologue 1; SPATA13, spermatogenesis associated 13 (also known as ASEF2); STARD, StAR-related lipid transfer domain containing; START, StAR-related lipid transfer domain; TIAM1, T cell lymphoma invasion and metastasis 1; TRIO, triple functional domain protein; TSC2, tuberous sclerosis 2. • ARRY-300
and deforolimus)
Philadelphia chromosome
The chromosome abnormality that causes chronic myeloid leukaemia, formed by a translocation between chromosomes 9 and 22, causing formation of the chimeric BCR-ABl1 tyrosine kinase.
Alternative splicing
A mechanism by which different forms of mature mRNAs are generated from the same gene, leading to the production of more than one related protein or isoform.
peptide, which is designated TGAT 65 . The TGaT transcript was detected in peripheral blood mononuclear cells from 14 of 21 patients with T cell leukaemia, but not in four control subjects. Ectopic expression of TGAT caused tumorigenic transformation of NIH 3T3 mouse embryo fibroblasts, although no evidence for T cell leukaemia growth was determined.
T cell lymphoma invasion and metastasis 1 (TIAM1), a Rac-specific GEF, is associated with various cancer types. First, it can function as a downstream effector of Ras 66 . Tiam1 -/-mice had impaired carcinogen-induced HRAS activation and squamous cell skin carcinoma formation, including fewer tumours and smaller tumour size, although the tumours that did form metastasized more readily 67 . Second, mouse models of adenomatous polyposis coli (APC)-induced colon cancer and ERBB2 (also known as neu)-induced mammary cancer also had impaired tumour formation in the absence of Tiam1, although in the case of the mammary cancer model the tumours were more invasive 68, 69 . Third, there are several reports of altered TIAM1 (mutation and overexpression) in various human cancers (Supplementary information S1 (table) ). Importantly, although TIAM1 might be important in tumour initiation, the increased malignancy and invasion on loss of TIAM1 in the skin and mammary models, and the observation that TIAM1 protein expression is lower during breast cancer progression 70 , suggests that TIAM1 may function as a metastasis suppressor; thus, inhibiting its activity in some settings might not be beneficial.
In addition to the DH-PH family of RhoGEFs, there is evidence for the aberrant function of the dedicator of cytokinesis (Dock) family RhoGEFs in cancer. In humans, this family is comprised of 11 members that possess a structurally distinct RhoGEF catalytic domain 71 . Interestingly, to date, Dock family proteins have been found to activate Rac or CDC42 but not RHOA 72 , although the structure of the RhoGEF catalytic DOCK homology region 2 (DHR2) domain bound to CDC42 suggests that they may activate a broader range of Rho GTPases 73 . DOCK1 (also known as DOCK180) is a RacGEF, and its overexpression together with its activator engulfment and cell motility 1 (ElMO1) was found to promote glioblastoma cell invasion in vitro and in vivo 74 . Dock RhoGEFs are also implicated in distinct facets of melanoma cell migration. DOCK10, a CDC42 GEF, was identified as a key regulator of protease-independent amoeboid melanoma cell migration 75 . By contrast, protease-dependent mesenchymal-type movement was driven by DOCK3, a RacGEF 76 . These results suggest distinct roles for CDC42 and Rac in the promotion of tumour cell migration.
ArfGEFs associated with cancer. ARF1 and ARF6, the most studied isoforms of the Arf GTPase subfamily, are active regulators of the proliferative and/or invasive properties of cancer cells, notably in melanoma and breast cancer cell lines 77, 78 , and have also been linked to resistance to apoptosis 79 . Their functions in invasion might result from their role at the crossroad between membrane trafficking and Rho GTPase-controlled actin remodelling, notably in the formation of invadopodia 12, 80 . Several subfamilies of ArfGEFs have recently emerged as candidate regulators that support the invasion of cancer cells. IQSEC1 (also known as BRAG2 and GEP100), an ARF6 GEF, has been implicated in breast cancer invasion 81 . IQSEC1 was overexpressed in primary ductal breast carcinomas, commonly with EGFR overexpression, and overexpression correlated with higher grade tumours 81 . RNAi-mediated knock down of IQSEC1, but not other ArfGEFs, reduced breast cancer cell invasion through Matrigel in vitro and reduced metastasis to the lung in a mouse model of breast cancer 82 . The expression of pleckstrin and Sec7 domain containing 1 (PSD1; also known as EFA6), an ARF6 GEF, is increased in glioma tissue samples, and its expression in a human gliobastoma cell line enhanced ERK-dependent invasion 83 . Overexpression of ARF6 
Farnesyltransferase
One of three human prenyltransferase enzymes, catalyses addition of a 15-carbon farnesyl group to proteins terminating with a CAAX tetrapeptide motif at the carboxyl terminus of a subset of Ras and Rho family GTPases.
has been reported in highly invasive breast cancer cell lines 82 . This may result from loss of expression of F-box protein 8 (FBx8), an unconventional ArfGEF that mediates the ubiquitylation of ARF6 and suppresses its activity 84 
GAPs in cancer
GAPs are the 'flip-side of the coin' to GEFs, and although less is known about them in general, many studies have demonstrated their crucial roles in curtailing GTPase activity in cancer. As activation of GEFs for the Ras superfamily GTPases has many roles in cancer, it is perhaps not surprising that loss of GAP activity allows uncontrolled GTPase activity and can promote cancer. We discuss some pertinent examples that demonstrate their importance and ways in which their activities are regulated below (see also Supplementary information S2 (table)). Although GAPs are generally tumour suppressors, there are also examples of oncogenic GAPs.
RasGAPs. The mutants of Ras are missense mutations (primarily at residues 12, 13 and 61) that impair the intrinsic and GAP-stimulated ability to hydrolyse GTP, rendering Ras constitutively GTP-bound and active in the absence of extracellular stimuli. Although the intrinsic activity of the GAPs is not altered in these cancers, the fact that they can no longer deactivate Ras indirectly implicates them in the oncogenic process. In this case, the RasGAPs would not be considered as drivers of this process. One of the earliest unsuccessful efforts made to develop anti-Ras drugs was the development of small molecules that restored GAP sensitivity to mutant Ras. figure) through post-translational processing, either signalled through the carboxy-terminal CAAX tetrapeptide motif or signalled through protein kinase Cα (PKCα)-dependent phosphorylation or ubiquitylation, are shown. Similar to Rho GTPases, Ras GTPases are also regulated by multiple guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). GTP-bound Ras interacts with various downstream effectors with diverse catalytic activities that possess Ras-binding domains (RBDs) or Ras-association (RA) domains. Although shown here as interactions with Ras, some are interactions restricted to specific Ras isoforms. * indicates that mutations are found in human cancers. AFAD, afadin (also known as AF6); FACE2, farnesylated proteins-converting enzyme 2 (also known as RCE1); FTase, farnesyltransferase; ICMT, isoprenylcysteine carboxyl methyltransferase; IMP1A, inositol(myo)-1(or 4)-monophosphatase 1; NF1, neurofibromin; PAT, palmitoyl acyl transferase; PLCε1, phospholipase Cε1; RAIN, Ras-interacting protein 1 (also known as RASIP1); RALGDS, Ral guanine nucleotide dissociation stimulator; RASA1, Ras GTPase-activating protein 1 (also known as p120RasGAP); RASA3, Ras GTPase-activating protein 3 (also known as GAP1IP4BP); RASA4, Ras GTPase-activating protein 4 (also known as CAPRI); RASAL1, Ras protein activator like 1; RASGRF, Ras protein-specific guanine nucleotide-releasing factor; RASGRP, Ras guanyl releasing protein; RASSF, Ras association domain family member; RGL, Ral guanine nucleotide dissociation stimulator-like; RGS, regulator of G-protein signalling; RIN, Ras and Rab interactor; SOS, son of sevenless homologue; SYNGAP1, synaptic Ras GTPase activating protein 1; TIAM, T cell lymphoma invasion and metastasis.
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StAR-related lipid transfer (START) domain
A ~200 amino acid motif initially identified as a lipid-binding domain.
Germline mutational loss of the NF1 tumour suppressor, which encodes the RasGAP neurofibromin, is found in patients with neurofibromatosis type 1 (REFs 85,86). Two recent sequencing studies found frequent somatic mutation of NF1 in glioblastoma (15-23% of the samples), and so this gene represented the fifth most frequently mutated gene in this cancer 15, 87 . Although some of the mutations are null mutations or truncations resulting in the loss of RasGAP catalytic function, which is consistent with its role as a tumour suppressor, the function of several of the point mutations that have been found remains to be determined. Post-translational loss of neurofibromin, which is induced by protein kinase C (PKC)-mediated proteasomal degradation, has also been observed in sporadic glioblastomas 88 .
As the only known catalytic function of neurofibromin is its RasGAP activity, the functional consequences of neurofibromin loss is attributed to the observed hyperperactivation of wild-type Ras. However, as the RasGAP domain constitutes only a small portion of the total protein, it has been suggested that other non-Ras-associated functions might exist.
The loss of another RasGAP, tuberin, which is a GAP for Ras homologue enriched in brain (RHEB) and RHEBl1 (REF. 89 ), is associated with tuberous sclerosis (TSC), which is a syndrome that is characterized by the formation of tumour-like lesions known as hamartomas in the kidney, lung, brain and skin 90 . This autosomal dominant disease is caused by germline and somatic mutational loss of either TSC1 (which encodes hamartin) or TSC2 (which encodes tuberin). Tuberin contains the RHEBGAP catalytic domain, whereas hamartin stabilizes tuberin and prevents its degradation; hence, the hamartin-tuberin complex is required for RHEBGAP activity 91 . Although the tumour phenotype is distinct, the increased incidence of renal cell carcinoma and other cancers in Eker rats, which have germline heterozygous Tsc2 mutations that inactivate the RHEBGAP activity of tuberin, supports the role of TSC2 as a tumour suppressor [92] [93] [94] . loss of TSC2 RHEBGAP function results in RHEB activation and persistent activation of its downstream effector mTOR. The functions of the hamartin-tuberin complex as a RHEBGAP are also regulated by phosphorylation, in particular AKT phosphorylates and thereby inactivates tuberin. Thus, genetic and biochemical activation of the PI3K signalling pathway (such as PIK3Ca gain-of-function or PTeN loss-of-function mutations) in cancer cells can also cause RHEB-mediated activation of the rapamycin-sensitive mTOR complex 1 (mTORC1).
RhoGAPs in cancer.
One RhoGAP in particular has recently stood out as having a central role as a tumour suppressor in several different cancer types: deleted in liver cancer 1 (DlC1; also known as ARHGAP7) 95, 96 . DLC1 was first discovered as a gene that is under-represented in a human hepatocellular carcinoma (HCC) specimen and that is deleted in HCC cell lines and tumours 97 . Subsequent studies found that DLC1 was deleted or transcriptionally silenced by promoter methylation in many cancer types (Supplementary information S2 (table) ). A comprehensive analysis of the genomic loss of DLC1 showed that heterozygous loss in tumours occurs at a rate that approaches that of TP53 (which encodes p53) mutation or loss in breast, lung, liver, colon and pancreatic tumours 98 . Additional studies identified two genes that encode DlC1-related proteins, stAR-related lipid transfer (sTART) domain-containing 13 (STaRD13; also known as DLC2) 99, 100 and STaRD8 (also known as DLC3) 101 , and the expression of both genes is lost in various human cancers, although it is unknown whether they are lost separately from or concurrently with DLC1. Finally, protein-protein interactions with 14-3-3 isoforms and another GAP, RASA1 (also known as p120RasGAP), may also cause loss of DlC1 function 102, 103 . Together with loss of expression in cancer, genetic and biochemical analyses in cell culture and mice provide functional evidence for DlC1 as a tumour suppressor. This role is demonstrated by the fact that N terminal truncations of sequences upstream of the DH-PH domains were responsible for creating the constitutively activated and transforming variants of RhoGEFs that have been identified in transformation or invasion assays. Some RhoGEFs are activated by phosphorylation at an N terminal motif that relieves the autoinhibitory activity. This is best characterized by SRC protein tyrosine kinase phosphorylation of the Vav family 154, 155 and other RhoGEFs 156, 157 . Other mechanisms of activation involve protein interaction with N terminal domains, such Gα 12 or Gα 13 interaction with the regulator of G protein signalling (RGS) box-containing RhoGEFs (ARHGEF1, ARHGEF12 (also known as LARG) and ARHGEF11) [158] [159] [160] , Ras interaction with the Ras-binding domain (RBD) in T cell lymphoma invasion and metastasis 1 (TIAM1) 66 and adenomatous polyposis coli (APC) association with the N terminus of ARHGEF4 (also known as ASEF) [161] [162] [163] . 
Druggability
The likelihood of being able to modulate the activity of a target protein with a small-molecule drug.
Ectopic re-expression of DlC1 in DLC1-deficient human tumour cell lines suppressed proliferation, anchorageindependent growth, invasion through Matrigel and xenograft tumour formation of various cancer types [104] [105] [106] [107] ; and re-expression in breast cancer cell lines reduced metastasis in a mammary fat pad orthotopic injection model 108 . In an ex vivo mouse model of Myc-induced tumorigenesis, knock down of endogenous DlC1 accelerated the onset of tumorigenesis and resulted in more aggressive tumours that resembled aggressive human HCC -providing strong evidence for the role of DlC1 as a tumour suppressor 98 . Similarly, ectopic expression of STARD13 or STARD8 in expression-deficient human tumour cell lines caused impairment in tumour cell growth 99, 101 . Although Dlc proteins are multi-domain proteins that are comprised of sterile α-motif (SAM), RhoGAP and START domains, evidence supports the crucial role of the RhoGAP domain in DlC1 tumour suppression. The substrates of DlC1 are RHOA, RHOB, RHOC, and to a lesser degree CDC42, but not Rac
107
; cell-based studies suggest that RHOA activation is a major consequence of DlC1 loss of function. In an ex vivo mouse model of Myc-induced liver tumorigenesis, activated RHOA pheno copied loss of DlC1 (REF. 98 ). Because of the high frequency of reduced Dlc expression in many different types of tumours, and the functional evidence that DlC1-3 are tumour suppressors, inactivation of which primarily inactivates Rho GTPases, alterations in this RhoGAP protein family represent the most common mechanism of altering Rho GTPase activity in human cancer.
Surprisingly, in contrast to the many RhoGEFs that are altered in cancer, except for the Dlc family, there is limited evidence for the role of other RhoGAPs in cancer. However, putative tumour suppressors, such as ARHGAP26 (also known as GRAF), ARHGAP25, ARHGAP5 and ARHGAP8, may exist (Supplementary information S2 (table)) but more work is required to validate these as tumour suppressors and to determine whether their RhoGAP activity is crucial. It could be that in many cancers GAP activity is normal, but that the excessive activation of GTPases through GEFs or GTPase overexpression overrides normal GAP-mediated inactivation.
ArfGAPs in cancer.
Two subfamilies of ArfGAPS, Agaps and Asaps, have been implicated in oncogenesis 11, 109 , although whether this is through their GAP activity towards Arf GTPases is not yet established. aGaP2 (also known as PIKe, centaurin-γ1 and GGaP2) is amplified and overexpressed in glioblastoma, prostate carcinoma and other cancers 79, 110, 111 . Cancer cells overexpressing AGAP2 resist apoptosis more strongly than those with normal expression levels, and ectopic expression of AGAP2 activates the AKT pathway and inhibits apoptosis in human glioblastoma cells, suggesting that the oncogenic properties of AGAP2 are mediated through the AKT pathway 79, [110] [111] [112] . AGAP2 is a multi-domain protein, which includes a domain that is remotely related to small GTPases 113 in addition to its ArfGAP domain. Whether these domains and/or the GAP domain are involved in the oncogenic effect remain unclear.
aSaP1 (also known as aMaP1, DDeF1 and centaurin-β4) overexpression is associated with invasive phenotypes in melanoma, prostate cancer and breast cancer cells [114] [115] [116] . ASAP1 has been best studied in breast cancer cells, where it co-localizes with ARF6 in invadopodia, and it is associated with proteins involved in actin remodelling 116 . A peptide derived from the C terminal SRC homology 3 (SH3) domain of ASAP1 prevented breast cancer cell invasion and metastasis 117 . A related ArfGAP, aSaP3 (also known as UPCL1, DDeFL1 and aCaP4), was identified by its upregulation in HCC 118 and is involved in migration and invasion in a mammary carcinoma cell line. However, ASAP3 is not involved in invadopodia formation and its localization is different from that of ASAP1, thus these two ArfGAPs probably have non-redundant functions 119 . In summary, as with GEFs, there are diverse genetic and biochemical mechanisms by which the function of GAPs, most commonly as tumour suppressors, is deregulated in cancer. However, to date, despite the large numbers of GAPs for Ras and Rho GTPases that have been identified, those that have been implicated in cancer remain limited. Perhaps this reflects the fact that there has traditionally been a greater focus on GEFs, or perhaps there is greater functional redundancy between GAPs, making it unlikely that loss of function of any one GAP will be sufficient to cause substantial deregulation of GTPase activity.
Targeting GEFs and GAPs: are they druggable? As most proteins that propagate information by intracellular protein-protein interactions, and therefore use large contact surfaces that lack the grooves and pockets for small-molecule interactions, GEFs and GAPs are not classically considered as druggable targets 120 . However, it is important to remember that the development of ATPcompetitive inhibitors of protein kinases, which were once considered undruggable, now constitute the major class of clinically useful anticancer drugs that target signal transduction. Therefore, druggability is primarily defined on current success and is not a static concept. Instead, the strength of target validation, rather than conventional wisdom, should prioritize efforts to establish target druggability.
GEFs: targets for anticancer drug discovery? With increasing evidence for aberrant GEF or GTPase activity in cancer, a logical issue is whether these regulatory proteins are attractive targets for anticancer drug discovery, particularly those GEFs that exhibit gain-of-function mutations or that are overexpressed. In addition, GEF activation defines where and when a GTPase is activated, and probably what the downstream events are, and thus GEFs are likely to convey high signalling specificity. This may also limit offtarget effects when inhibited. The structures of representative GTPase-GEF complexes have been determined [121] [122] [123] , all feature a very large protein-protein interface that results from the structural remodelling of the small GTPase upon binding. The shape, structural dynamics and chemistry of GEF-GTPase interaction surfaces are thus very different from those of catalytic sites of enzymes, such as the ATPbinding site of signalling kinases, and therefore might appear to be inappropriate for small-molecule binding. 
Nature Reviews | Cancer
G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G G C C C C C C C C C C C U U U U U U U U U U U U U U U U U U U U U UU U 5 3ʹ 5ʹ
M69
Sec7 domain
ArfGEF catalytic domain, named after the first protein that it was identified in S. cerevisiae sEC7.
Aptamer
A double-stranded DNA, single-stranded RNA or peptide that binds to specific molecular targets, such as a protein or metabolite. Aptamers are usually selected from large libraries of synthesized molecules.
However, despite this perception, we summarize the experimental evidence that indicates it might be feasible to develop small-molecule inhibitors of GEFs below.
Brefeldin A (BFA) has been instrumental in establishing that GEFs can be inhibited by small molecules, and is by far the best characterized GEF inhibitor -although this characterization took approximately 40 years since its discovery as a natural product that was isolated from the fungus eupenicillium brefeldianum in the late 1950s 124 . The combination of yeast genetics, biochemistry and structural biology has demonstrated that BFA targets the complex between Arf-GDP and the catalytic domain (the sec7 domain) of an ArfGEF at the beginning of the exchange reaction [125] [126] [127] [128] . BFA binds at the interface between the two molecules, which freezes the complex in an abortive conformation that cannot proceed to nucleotide exchange (FIG. 5) . This inhibitory mechanism is remarkably efficient at inhibiting Arf-regulated traffic at the Golgi apparatus in live cells 129, 130 . Furthermore, the fact that BFA contacts both Arf-GDP and the ArfGEF in the abortive complex allows it to have a restricted specificity for a subset of both ArfGEFs and Arf GTPases. Notably, BFA discriminates between ARF1-GDP and ARF6-GDP, despite their similarity, emphasizing that conceptually almost any level of specificity can be achieved however similar the targets may seem 131 . BFA has demonstrated several anticancer effects in cells, although whether these effects result from the impairment of ArfGEF functions has not yet been formally addressed.
The extensive analysis of the mechanism of action of BFA led to the general concept of interfacial inhibition, which refers to inhibitors that function by stabilizing protein complexes and target regions in or near interacting interfaces 128 (FIG. 5b) . Some inhibitors of natural origin that are already used in the clinic have been recognized as interfacial inhibitors, such as the anticancer drugs vinblastine and camptothecin, suggesting a new avenue to therapeutic intervention that has begun to be explored 132 . lM11 was discovered by an in silico screen based on this concept, and was shown to target an interfacial depression at the surface of the complex between ARF1-GDP and BFA-insensitive GEFs such as ARNO (also known as CYTH2) and was also shown to block ARNO-dependent cellular migration 133 . A few other promising examples of cell-active small-molecule ArfGEF inhibitors have been selected using in vitro 134, 135 and phenotypic screens 136 . These studies demonstrate that despite the high homologies within a given GEF family, GEF-specific inhibitors can be developed. Therefore, the specific flexibility and conformational changes that characterize small GTPase-GEF complexes are likely to be advantageous to drug development, notably for interfacial inhibitors. However, the design of high-throughput biochemical assays to screen effectively for such inhibitors remains a challenge 132 .
There has also been a recent increase in the discovery of inhibitors of Rho GTPase activation. Inhibitors that target specific RhoGEFs have been discovered by highthroughput screens. The first example was an aptamer Figure 5 | Inhibition of GeFs by brefeldin a and related molecules. a |The crystallographic structure of the Arf-GDP-Sec7 complex inhibited by brefeldin A (BFA) is shown. BFA (red) 'sneaks' into a hydrophobic cavity at the interface between the small G protein Arf (green) and the catalytic domain of its guanine nucleotide exchange factor (GEF; blue), where it establishes tight hydrophobic and polar contacts with both partners of the complex 127, 128 . Nature probably selected this low-affinity intermediate (>100 mM) because its energy is unbalanced. This unbalance triggers the conformational change that secures GTP-bound Arf to membranes in the unperturbed reaction 
Fluorescence polarization
A technique specially applied to study molecular interactions. When fluorescent molecules in solution are excited with plane-polarized light, they will rotate and tumble, and the planes into which light is emitted can be very different from the plane used for initial excitation.
RGS domain
Functions in a similar manner to GTPase-activating proteins by accelerating the intrinsic GTP hydrolysis activity of heterotrimeric Gα subunits, causing inactivation of GPCR signalling.
C1 zinc finger domain
An ~50 amino acid phospholipid binding domain. It typically binds membrane-bound phorbol esters or diacylglycerol to promote membrane localization.
screen in which peptides coupled to thioredoxin were selected in yeast for their binding to the second DH domain (which specifically activates RHOA) of TRIO 137 . This identified a potent inhibitor of TRIO, which was subsequently optimized to inhibit its oncogenic splice variant TGAT 138 . The corresponding optimized peptide was active in cells in vitro and reduced TGAT-induced tumour formation in xenograft models. Another assay screened a small chemical compound library by monitoring the interaction of the GTPase with an effector in the presence of a co-expressed GEF 139 . This yeast three-hybrid assay identified several inhibitors of RHOG activation by TRIO. One of these, ITx3, was specific and active in cellbased assays 140 . Screening using a fluorescence polarization guanine nucleotide-binding assay also identified smallmolecule inhibitors of ARHGEF12-stimulated RHOA nucleotide binding in vitro 141 . Although the inhibitors and aptamers that were discovered in these screens were of low potency, they support the potential for identifying GEF-targeted inhibitors.
Another related example of a way to target GTPase activity is through targeting the surface of the GTPases that are required for GEF activation. Through computational screening of the surface of RAC1 that is known to interact with GEFs, the small molecule NSC23766 was discovered, which inhibited activation of RAC1 by the Rac-specific GEFs TRIO and TIAM1, but not GEF activation of RHOA or CDC42 in vitro and in cells 142 . using a similar strategy, and using structural information from NSC23766 in complex with RAC1, five additional small molecules, that were structurally unrelated to NSC23766, were discovered that could specifically block Rac activation by GEFs 143 . These molecules do not directly target GEFs, and are likely to lack GEF specificity as they would block the surface of GTPases and thus activation by various GEFs. They could nonetheless provide an interesting approach to block GEF activation of Rho or other small GTPases that are important in cancer.
GAP-targeted therapies.
RasGAPs stimulate the intrinsic GTPase activity of Ras by up to 10 5 -fold, but have almost no effect on oncogenic Ras mutants 144 . Therefore, one strategy has been to identify small molecules that restore the sensitivity of oncogenic Ras mutants to RasGAPs. However, despite great effort, this was unsuccessful, probably because oncogenic mutations disturb the active site of Ras, preventing the proper transition state that is needed for GAP-mediated hydrolysis 145 . Thus, even if GAP activity of RasGAPs was increased by small molecules, Ras will probably still be insensitive to this higher activity. The involvement of GAPs in cancer is most commonly associated with loss of function, and hence they exhibit properties of tumour suppressors; although, as listed in Supplementary information S2 (table), some GAPs may have oncogenic properties and could therefore be drug targets. As it is traditionally easier to develop small-molecule antagonists rather than agonists, GAPs are less attractive targets. Instead, because loss of GAP function leads to GTPase activation, most efforts have been focused on blocking the persistent GTPase effector signalling that occurs.
There is limited but promising evidence that it might be possible to develop small-molecule modulators of Ras superfamily GAPs. High-throughput screening identified small-molecule inhibitors of regulator of G protein signalling domains (RGs domains), which are GAPs for heterotrimeric G proteins 146 . Despite their low structural homology to RasGAPs, they share a similar enzymatic transition state 145 , suggesting that this could be a starting point for the design of Ras superfamily GAP inhibitors. One class of RhoGAPs, the Rac-selective chimaerins (CHN), possess C1 zinc finger domains that bind diacyl glycerol, a cofactor for their activity 26 . Therefore, small molecules that bind C1 domains may activate their GAP activities, causing the downregulation of Rac GTPase activity 26 . Although such a therapeutic approach will be complicated by the existence of other proteins with C1 domains (such as RASGRP1), there is evidence that C1-binding molecules can have some degree of selectivity for a subset of C1-containing proteins. This approach may be a therapeutic option for cancer in which there is RacGEF-mediated activation of Rac.
Future directions
We have highlighted key evidence for the role of aberrant expression and function of GEFs and GAPs of Ras superfamily small GTPases in cancer, with an emphasis on the two key early steps in cancer drug discovery: target validation and druggability. With the continued application of genome-wide analyses of cancer cells, additional correlative evidence for aberrant GEF and GAP expression and function is expected to continue at a rapid rate, although validation of their functional importance in cancer will be a rate-limiting factor. Even the current body of experimental evidence validating GEFs and GAPs will require more rigorous investigation. Although RNAi-based analyses have contributed crucial validation, the multi-domain and multi-functional nature of GEFs and GAPs emphasizes that caution must be exercised in simply concluding that any phenotypic alterations are solely due to their roles in regulating GDP-GTP cycling of small GTPases. For example, RAlGDS can activate AKT independently of its RalGEF function 147 . Is the impaired HRAS-driven skin tumour formation due to the ablation of RAlGDS expression that is caused by the loss of Ral or by AKT activation, or both? Rescue experiments with carefully designed GEF or GAP domain-impaired mutants are needed to access possible GEF-independent or GAP-independent functions of these regulatory proteins.
Furthermore, although analyses of mouse models in which a deficiency of a GEF or a GAP is achieved at the onset of tumour formation provide important validation, these studies validate the preventive value rather than the therapeutic value with a pre-existing tumour. For example, TIAM1 was shown to be necessary for the initial growth of HRAS-induced skin tumours, but mice lacking Tiam1 had more aggressive tumours when they did arise 67 . Finally, genetic ablation of a target is not equivalent to pharmacological inhibition of a target. This is dramatically demonstrated with studies that showed that preventing Ras binding to PI3K but not pharmacological Nature Reviews | Cancer Regarding druggability, it is still very early days in this phase of drug discovery, with the current body of evidence more one of proof of concept and less one of identifying promising leads for clinical evaluation. The lessons learned from BFA currently provide the best evidence for the tractability of GEFs. Perhaps chemical libraries that are based on such natural products will be a more fruitful direction than the traditional use of libraries that are based on chemical structures that have been derived from the past success with enzymes and GPCRs. As the processes and paradigms of drug discovery continue to evolve, so will the definition of druggability. With advances in the use of structural information in virtual screening, structure-based design, fragment-based library screening, coupled with functional screens that are focused on protein complexes rather than isolated proteins, perhaps GEFs and GAPs can be rendered druggable. That protein kinases, currently the 'low-hanging fruit' of anticancer drug discovery, may be key regulators of GEFs and GAPs and their downstream signalling pathways, suggests that more conventional directions for GEF and GAP drug discovery are also promising directions (FIG. 6) .
Figure 6 | Signalling networks regulated by ras and rho family GTPases in cancer.
In contrast to Ras, the specific downstream effectors that mediate the cancer cell phenotype, proliferation and survival, invasion and metastasis of other Ras and Rho family GTPases remain poorly understood. In this figure, we highlight protein kinases (PKs; dark blue) as effectors or regulators of Ras and Rho family GTPases in oncogenesis. First, analogous to the role of Raf in Ras function, protein kinases have been implicated as downstream effectors of GTPase-mediated oncogenesis. In particular, there is evidence that the Rho-associated, coiled-coil containing protein kinase (ROCK) [164] [165] [166] , myotonic dystrophy kinase-related CDC42-binding kinase (MRCK) 167 , p21-activated kinase (PAK) [168] [169] [170] [171] and activated CDC42 kinase 1 (ACK1; also known as TNK2) 172, 173 protein kinase effectors can promote oncogenesis. Much of the evidence for ROCK involvement in cancer is based on studies with ROCK inhibitors 174 . However, as these inhibitors have considerable off-target activities, it is unclear whether ROCK inhibition alone accounts for the antitumour activities of ROCK inhibitors. There is emerging evidence that protein phosphorylation is an important mechanism for regulation of small GTPase function, often by controlling subcellular localization and interaction with other proteins. Protein kinase Cα (PKCα) phosphorylation causes KRAS translocation from the plasma membrane to the mitochondria, where KRAS association with BCL2-associated agonist of cell death (BAD) results in apoptosis 175 , suggesting that agonists of PKCα may function as KRAS-directed therapies. Similarly, aurora kinase A (AURKA) phosphorylation of RALA is essential for RALA-mediated promotion of pancreatic cancer cell line tumorigenic growth 176 . Additional effectors of Rho GTPases that regulate actin organization (such as MDIA; also known as diaphanous homologue 1 (DIAPH1)) may influence cell motility, and will therefore be important mediators of Rho GTPase induction of tumour cell invasion and metastasis 177 . A second theme is the signalling crosstalk that can occur between different members of the Ras and Rho families. For example, RALA binding protein 1 (RALBP1) -an effector of Ral -functions as a Rho GTPase-activating protein (GAP) for Rac and cell division cycle 42 (CDC42) inactivation associated with transformation 176 . Ras activation of mTOR can involve AKT activation, leading to inactivation of tuberous sclerosis 2 (TSC2; also known as tuberin), causing Ras homologue enriched in brain (RHEB) activation. APC, adenomatous polyposis coli; Dlc, deleted in liver cancer; DOCK3, dedicator of cytokinesis 3; ECT2, epithelial cell transforming sequence 2 oncogene; EGFR, epidermal growth factor receptor; EXOC2, exocyst complex component 2 (also known as SEC5); GEF, guanine nucleotide exchange factor; NF1, neurofibromin; NF-κB, nuclear factor-κB; PLK1, polo-like kinase 1; PREX2, phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2; TBK1, TANK-binding kinase 1.
ROCK
A serine/threonine kinase that is an effector of RHOA and RHOC and phosphorylates proteins that regulate actin stress fibre formation and focal adhesion assembly.
MRCK
serine/threonine kinases that preferentially bind to activated CDC42 and phosphorylate proteins that regulate actin reorganization.
